One of AstraZeneca's key prospects in oncology, selumetinib, has failed in at the Phase III stage in one of its potential indications, uveal melanoma.
One of AstraZeneca's key prospects in oncology, selumetinib, has failed in at the Phase III stage in one of its potential indications, uveal melanoma.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
